Julien Coste
Director of Finance/CFO presso INTRASENSE
Profilo
Julien Coste is currently the Chief Executive Officer at Biovertis AG since 2018.
He also holds a position as Director-Finance & Administration at Intrasense SA. Previously, he served as Director-Finance & Administration at Neuro3D SA and Chief Financial Officer at Deinove SA in 2012.
Mr. Coste has a graduate degree from Université Paris Dauphine-PSL and an undergraduate degree from Ecole Superieure Commerce Grenoble Business School.
Posizioni attive di Julien Coste
| Società | Posizione | Inizio |
|---|---|---|
| INTRASENSE | Director of Finance/CFO | - |
Biovertis AG
 Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Chief Executive Officer | 22/08/2018 |
Precedenti posizioni note di Julien Coste
| Società | Posizione | Fine |
|---|---|---|
| DEINOVE | Director of Finance/CFO | - |
Neuro3D SA
 Neuro3D SA Pharmaceuticals: OtherHealth Technology Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France. | Director of Finance/CFO | - |
Formazione di Julien Coste
| Université Paris Dauphine-PSL | Graduate Degree |
| Ecole Superieure Commerce Grenoble Business School | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INTRASENSE | Technology Services |
| Aziende private | 3 |
|---|---|
Neuro3D SA
Neuro3D SA Pharmaceuticals: OtherHealth Technology Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France. | Health Technology |
Biovertis AG
Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Health Technology |
Deinove SA
 Deinove SA BiotechnologyHealth Technology Deinove SA is a biotechnology company, which engages in the development of new-generation anti-infective antibiotics and bioactives. Its portfolio include Phy-N-Resist and HEBELYS. The company was founded by Philippe Pouletty and Miroslav Radman on October 11, 2006 and is headquartered in Grabels, France. | Health Technology |
- Borsa valori
- Insiders
- Julien Coste
